In vitro chemoresponse in metachronous pairs of ovarian cancers

An in vitro chemoresponse assay may aid effective therapy selection in epithelial ovarian cancer (EOC). This study explores changes in chemoresponse between paired primary and recurrent EOC tumors. RESULTS from metachronous tumors were examined in 242 patients. Changes in in vitro chemoresponse, mea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anticancer research 2014-12, Vol.34 (12), p.7191-7196
Hauptverfasser:	Dalton, Heather J, Fiorica, James V, Edwards, Robert P, Benjamin, Ivor, Rocconi, Rodney P, Recio, Fernando O, Lovecchio, John L, Burrell, Matthew O, Shahin, Mark S, Grendys, Edward C, Wang, Dakun, Wang, Tianhua, Monk, Bradley J
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Carcinoma, Ovarian Epithelial Disease-Free Survival Drug Resistance, Neoplasm Female Humans Neoplasm Recurrence, Local - drug therapy Neoplasms, Glandular and Epithelial - drug therapy Neoplasms, Glandular and Epithelial - mortality Neoplasms, Second Primary - drug therapy Neoplasms, Second Primary - mortality Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	An in vitro chemoresponse assay may aid effective therapy selection in epithelial ovarian cancer (EOC). This study explores changes in chemoresponse between paired primary and recurrent EOC tumors. RESULTS from metachronous tumors were examined in 242 patients. Changes in in vitro chemoresponse, measured by the area under the dose response curve (AUC) between paired tumors were assessed. A significant increase in AUC was identified in most first-line therapies over time. No significant difference was observed in most recurrent therapies. When the elapsed time between occurrences was
ISSN:	1791-7530